TT  UT Horizon Fund

https://www.uts-innovation.com/horizon-fund





     Office Locations:

210 West 7th Street
Colorado Bldg., Suite 6.620
Austin, TX 78701
Phone: 512-499-4495
Fax: 512-322-3786

 

Stages:

  • Early
  • Seed


 

Industries:

  • Communications & Networking
  • Information Technology
  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    The University of Texas System helps support commercialization activities through the UT Horizon Fund, a strategic venture fund. The UT System has a foundation of 154 active startups, including 20 new startups in FY 2011 and 62 active invested startups. Capitalized in 2011 with a $10 million investment and recapitalized in 2013 with an additional $12.5 million, the UT Horizon Fund serves as the strategic venture fund to act as catalyst for commercialization. The UT Horizon Fund is evergreen, where returns are re-invested for future growth and development.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Gus Johnson Assistant Director
    Julie Goonewardene Chief Innovation Officer and Managing Director
    Mary Zimmerman Administrative Associate
    Teresa Ferguson Administrative Associate

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      12/12/2017


      GenXComm


      TX


      $7,000,000


      Series A


     

    Portfolio companies include:


      Aeglea Biotherapeutics
        web link


      Alafair Biosciences
        web link


      Apollo Endosurgery
        web link


      Cardiovate
        web link


      Cerevast
        web link


      FibeRio Technology
        web link


      GenXComm
        web link


      Latakoo
        web link


      Lung Therapeutics
        web link


      M87
        web link


      MicroTransponder
        web link


      PLx Pharma
        web link


      Rapamycin Holdings
        web link


     

    Recent News: